

Publications / Veröffentlichungen

Döhner H, Schlenk R, Fischer J Th, del Valle F, Pezzutto A, Pfreundschuh M, Weber W,
Distelrath A, Bürger M, Haas R, Fischer K, Hunstein W.

Stratification of Postremission Therapy in Adult Acute Myeloid Leukemia According to the Karyotype.
Preliminary Results of a Multicenter Treatment Trial (AML HD93)
Annals of Hematology, Suppl. II to Vol. 70 # 160 (1995)

Döhner H, Schlenk R, Fischer J Th, del Valle F, Pezotto A, **Distelrath A**, Hartmann F, Weber W, Bürger H, Göckel F, Haas R, Fischer K, Hunstein W.

Stratification of Postremission Therapy in Adult Acute Myeloid Leukemia According to the Karyotype.
Preliminary Results of a Multicenter Treatment Trial (AML HD93)
Onkologie Suppl. 2 zu Band 18 Oktober 1995 #38

Schlenk R, Döhner H, Pförsisch M, **Distelrath A**, Fischer J Th, Bürger H, Fischer K, Haas R, Hunstein W.
Mobilization op Peripheral Blood Progenitor Cells in Patients witz Acute Myeloid Leukemia Following
Intensive Induction Chemotherapy and Consolidation with High-Dose Cytarabine/Mitoxantrone + G –
CSF.

Onkologie Suppl. 2 zu Band 18 Oktober 1995 #570

Klinker H, Schwarzkopf A, Junger O, Kühnlein L, Langmann P, **Distelrath A**.

Prävention von Aspergillose-Erkrankungen im Rahmen von Baumaßnahmen bei laufendem
Klinikbetrieb.

Immunität und Infektion, Suppl. 1/95, p. 94 (1995)

Ranke O, **Distelrath A**, Hellinger A, Arps H, Höffkes H-G, Kaelble T.

Intensified ELDP (etoposide, liposomal doxorubicin, cisplatin) chemotherapy combined with
mitotane in a patient with advanced and relapsed metastatic non-functional adrenal carcinoma.
Onkologie 2005; 28: #876 (Abstract)

Ranke O, Hofmann E, **Distelrath A**, Höffkes H-G.,

Renal cell cancer presenting witz leptomeningeal carcinomatosis responding to sorafenib.

Onkologie 2007; 30: 450-451 (Kasuistik)

Ranke O, Höffkes H-G, Feldmann H-J, **Distelrath A**, Fassbinder W, Greim C-A, Meissel R.

Interdisziplinäres Fachkonzept für die palliativmedizinische Versorgung onkologischer Patienten
durch das Palliativzentrum Osthessen der Klinikum Fulda gAG.

3. Fachtagung „Palliative Versorgung und hospizliche Begleitung in Hessen“
31.01.2007 Bad Nauheim (Poster)

Susanne Schnittger,¹ Ulrike Bacher,² Claudia Haferlach,¹ Dietrich Beelen,³ Peter Bojko,⁴ Dieter
Bürkle,⁵ Robert Dengler,⁶ **Andrea Distelrath**,⁷ Michael Eckart,⁸ Robert Eckert,⁹ Stefan Fries,¹⁰ Jan
Knoblich,¹¹ Georg Köchling,¹² Hans-Peter Laubenstein,¹³ Petro Petrides,¹⁴ Manfred Planker,¹⁵ Rudolf
Pihusch,¹⁶ Rudolf Weide,¹⁷ Wolfgang Kern,¹ and Torsten Haferlach¹

Characterization of 35 new cases with four different MPLW515 mutations and essential
thrombocytosis or primary myelofibrosis

Haematologica. 2009 January; 94(1): 141–144.

Published online 2008 November 23. doi: 10.3324/haematol.13224.

Members of the German-Austrian Study Group AMLSG.

Insertion of FLT3 Internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

Blood, Kayser et al. Vol. 114, Issue 12, p 2386-2392, September 17, 2009

Kaufmann M, Maas N, Costa S d, Schneeweiss A, Loibl S, Sütterlin M W, Schrader I, Gerber B, Bauer W, Wiest W, Tome O, **Distelrath A.**, Hagen V, Schreier J, Ruckhäberle E, Metha K, von Minckwitz G. First line therapy with moderate dose Capecitabine in metastatic Breast Cancer ist safe and effective – Results of the MONICA Trial European Journal of Cancer (2010) doi:10.1016/j.ejca.2010.07.009

Co Autor **Distelrath A.**,

Erste Publikation zur Post-Marketing-Surveillance-Studie über Noxafil: Posaconazole in Invasive Mycoses at Daily Medical Course An On-Line Based, Prospective, Observational Survey – Safety and Tolerability

Original Article prepared for JAC, 2010

Frank O., Mügge L.-O., Scheid C., Schäfer E., Lück A., Scheidegger C., **Distelrath A.**, Plewe D., Gausch G., Bruhn P., Korsten S., Maywald O., Sauer U., Söling U., Heits F., Blumenstengel K., Lakner V., Lerchenmüller C., Ritter U., Hochhaus A.

Increasing the dose of Imatinib (IM) is well tolerated and leads to clinical improvement in a significant number of patients (pts) with Chronic Myeloid Leukemia (CML) – first data of the observation DOSING study.

P507 DGHO 2010

Andrea Distelrath, Barbara Scheffler, Melanie Laszczyk

Pilot-Erfahrungen zur Therapie und Prophylaxe von Hautveränderungen unter Chemo- bzw.

Radiochemotherapie mit Betulin-Emulsionen

Zeitschrift für Phytotherapie 2010; 31: 179-184

Gebhard, S., **Distelrath, A.**, Grothe, W., Höffkes, H.-G.

Combined chemotherapy of Rituximab, Fludarabine and Cyclophosphamid (R-FC) is superior in younger patients with B-CLL with respect to molecular remission rates

P818, DGHO Berlin, 2010

Schneeweiss A., Förster F., Hollburg W., Tesch H., Klare P., Wülfing P., **Distelrath A.**, Schumacher C., Steffens C.-C., Schubert R., Widing A., Kasper C., Schmidt M.

First-line Bevacizumab combined with Paclitaxel in triple-negative locally recurrent/metastatic Breast Cancer: subpopulation analysis of 115 patients treatet in routine oncology practice in Germany

P2-16-12 SABCS 2010 und #78311 ASCO 2011 und #5.073 EMCC 2011

Dengler J., Coutre P., Stegelmann F., Scheid C., Weide R., Illmer T., Sauer A., Walter M., Schneider-Kappus W., Kröger M., **Distelrath A.**, Stier G., Stern S., Schlegel F., Meincke M., Frank o., Ottmann O.G.

Nilotinib in routine clinical management of CML patients failing prior therapy: Update of the German TARGET study

P886 DGHO 2011-11-24

Möhler M., Kanzler S., Schimanski C.C., Wörns M.A., Denzer U., Kolligs F., Ebert M., **Distelrath A.**, Zeuzem S., Lammert F., Geissler M., Lohse A., Dollinger M., Lindig U., Dürr M., Lubomierski N., Kabisch M., Schadmand-Fischer S., Galle P.R. AIO
A randomized, double-blind, multicenter phase II AIO trial with Gemcitabine plus Sorafenib versus Gemcitabine plus placebo in patients with chemo-naïve advanced or metastatic biliary tract cancer: first safety and efficacy data
80719 ASCO 2011 und V736 DGHO 2011-11-24

SABCS 2014: Advanced Disease Treatment

4EVER - Final analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE).

H Tesch, O Stoetzer, T Decker, C Kurbacher, R Neumeister, F. Marme', A Schneeweiss, C Mundhenke, **A Distelrath**, P Fasching, M Lux, D Lueftner, P Hadji, W Janni, M Muth, J Kreuzeder, D Wallwiener

SABCS 2014: PROGNOSTIC AND PREDICTIVE FACTORS

4EVER: mTOR inhibition has a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with everolimus (EVE) in combination with exemestane (EXE)

P Hadji, H Tesch, O Stoetzer, T Decker, C Kurbacher, R Neumeister, F Marme', A Schneeweiss, C Mundhenke, **A Distelrath**, P Fasching, M Lux, D Lueftner, W Janni, M Muth, J Kreuzeder, E Grischke

ASCO 2016 Abstract

Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice – 1st interim analysis of the national non-interventional study (NIS) HerSCin

Author(s): Schmidt M, Kümmel S, Ruf-Dördelmann A, **Distelrath A.**, Wacker J, Dietrich M, Schmatloch S, Lüdtke-Heckenkamp K

ESMO 2017 Abstract

Second interim analysis of HerSCin, a German non-interventional study of subcutaneous trastuzumab (HSC) therapy for HER2-positive early breast cancer (eBC) treated in routine clinical practice

Kerstin Luedtke-Heckenkamp, Sherko Kummel, Antonia Ruf-Doerdelmann, **Andrea Distelrath**, Juergen Wacker, Sabine Schmatloch, Saskia Busch-Liles, Marcus Schmidt

Journal: Journal of Bone Oncology

Title: The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Corresponding Author: Peyman Hadji

Co-Authors: Hans Tesch, Oliver Stoetzer, Thomas Decker, Christian M. Kurbacher, Frederik Marmé, Andreas Schneeweiss, Christoph Mundhenke, **Andrea Distelrath**, Peter Fasching, Michael Lux, Diana Lüftner, Wolfgang Janni, Mathias Muth, Julia Kreuzeder, Claudia Quiering, Eva-Maria Grischke

Abstract: IKCS 2022

und 04/2023

Real-World Clinical Outcomes of tivozanib as first-line treatment for advanced renal cell carcinoma of metastatic renal cell carcinoma in Germany

Authors and Affiliations

Viktor Grünwald (Universitätsklinikum Essen), Karen Rußwurm (Bonifatius Hospital; Lingen), Ralf Eckert (Urologische Arztpraxis in Eisleben), Sandra Seseke (Urologische Praxis; Halle), Diana Standhaft (Klinik für Urologie, Kinderurologie und urologische Onkologie, Städtisches Klinikum Dessau), Martina Stauch (Ambulantes Zentrum für Hämatologie/ Onkologie/ Gerinnung), Susanne Kloß (KMG Klinikum; Luckenwalde), Monika Schiffer (Kliniken Sindelfingen), Jan Dieckhoff (Praxis Dieckhoff), Steffen Baumann (Praxis Dr. Baumann), Horst Brenneis (Praxis Dr. Brenneis), Michael Seidel (Praxis Dr. Oetzel), Olrik Rau (Praxis Dr. Rau), Silke Schirrmacher-Memmel (Studienzentrum Aschaffenburg), Eva Hellmis (Urologicum Duisburg), Claus F. Fieseler (Urologie Fieseler), Christian Doebe (Urologikum Lübeck), Wolfgang Hölzer (ÜBAG Degen/Hölzer/Hoch Facharztpraxis für Urologie), Carsten Ziske (GOSPL Ziske; Troisdorf), **Andrea Distelrath** (Gem. Praxis Distelrath; Wilhelmshaven) Norbert Marschner (Praxis für interdisziplinäre Onkologie und Hämatologie) Philipp Ivanyi (Medizinische Hochschule Hannover), Carsten Lange (Urologisch-onkol. Schwerpunktpraxis Bernburg), Andreas Janitzky (Uniklinikum Magdeburg); Martin Bögemann (Universitätsklinikum; Münster)

Abstract: ESMO BC, May 2022

Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC)

Nadia Harbeck, Denise Wrobel, Matthias Zaiss, Dagmar Guth, **Andrea Distelrath**, Jürgen Terhaag, Andreas Lorenz, Rupert Bartsch, Urs Breitenstein, Michael Schwitter, Marija Balic, Christian Jackisch, Volkmar Müller, Gabriel Rinnerthaler, Marcus Schmidt, Khalil Zaman, Timo Schinköthe, Diana Lüftner

Background

Poster: ESMO GI 2022 World Congress on Gastrointestinal Cancer Abstract

ASCO-GI 2023

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria - BERING CRC

TRACE: DGHO Abstract 2022

Thema: Mammakarzinom

Tucatinib in patients with locally advanced or metastatic HER2-positive breast cancer who received at least two prior anti-HER2 treatment regimens: Study design of the non-interventional study TRACE

Tucatinib bei Patienten mit lokal fortgeschrittenem oder metastasiertem HER2+ Mammakarzinom, die zuvor mit mindestens zwei anti-HER2-basierten Therapieregimen behandelt wurden: Studiendesign der nicht-interventionellen Studie TRACE

Welt A¹, Distelrath A², Losem C³, Müller L⁴, Reschke D⁵, Schöttker B⁶, Zahn MO⁷, Zaiss M⁸, Altmann M⁹, Bentmann E⁹, Friedrich J⁹ de Buhr R¹⁰, Hanselmann J¹⁰, Hogrefe C¹⁰, Marschner N¹⁰, Potthoff K¹⁰

Abstract: 287 SGBCC 2023

Topic: Adjuvant systemic therapy

Interim analysis of ELEANOR (n=200): a multi-national, prospective, noninterventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib

R. Bartsch , N. Harbeck , D. Wrobel , M. Zaiss , J. Terhaag , D. Guth , A. Distelrath , R. Wuerstlein , M.-O. Zahn , D. Lüftner , M. Schwitter , M. Balic , C. Jackisch , V. Müller , G. Rinnerthaler , M. Schmidt , K. Zaman , T. Schinköthe , M. Gorray , U. Breitenstein